Verteporfin
- Atc Codes:S01LA01
- CAS Codes:129497-78-5
- PHARMGKB ID:129497-78-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Visudyne; Belgium: Visudyne; Bulgaria: Visudyne; Czech Republic: Visudyne; Denmark: Visudyne; Estonia: Visudyne; Finland: Visudyne; France: Visudyne; Germany: Visudyne; Greece: Visudyne; Hungary: Visudyne; Ireland: Visudyne; Italy: Visudyne; Latvia: Visudyne; Lithuania: Visudyne; Luxembourg: Visudyne; Netherlands: Visudyne; Poland: Visudyne; Portugal: Visudyne; Romania: Visudyne; Slovakia: Visudyne; Spain: Visudyne; Sweden: Visudyne; UK: Visudyne.
North America
Canada: Visudyne; USA: Visudyne.
Latin America
Argentina: Visudyne; Brazil: Visudyne.
Asia
Japan: Visudyne.
Drug combinations
Chemistry
Verteporfin: C~41~H~42~N~4~O~8~. Mw: 718.79. (1) 23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-; (2)(±)-trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,9-trimethyl ester mixture with (±)-trans-3,4-dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid, 3,4,13-trimethyl ester. CAS-129497-78-5 (1993).
Pharmacologic Category
EENT Drugs, Miscellaneous. Ophthalmic Agent. (ATC-Code: S01LA01).
Mechanism of action
Following intravenous administration, verteporfin is transported by lipoproteins to neovascular endothelium in affected eye(s), including choroidal neovasculature and retina. Verteporfin must then be activated by nonthermal red light, which results in local damage to endothelium, leading to temporary choroidal vessel occlusion.
Therapeutic use
Treatment of predominantly classic subfoveal choroidal neovascularization due to macular degeneration, presumed ocular histoplasmosis, or pathologic myopia.
Pregnancy and lactiation implications
There are no adequate, well-controlled studies in pregnant women. Use only if potential benefit to mother outweighs potential risk to fetus. Not recommended in nursing women.
Unlabeled use
Predominantly occult subfoveal choroidal neovascularization.
Contraindications
Hypersensitivity to verteporfin or any component of the formulation. Porphyria.
Warnings and precautions
Infusion reactions (chest pain, vasovagal and hypersensitivity reactions) occurred rarely. Photosensitivity. Use with caution in the following cases (not studied): biliary obstruction, moderate-to-severe hepatic impairment, in patients under anesthesia. Patients ≥75 years of age less likely to benefit from therapy. Do not retreat patients who experience decrease of vision ≥4 lines within 1 week of treatment unless vision recovers and potential benefits and risks are carefully considered. Patients with dark irides, occult lesions, or <50% classic choroidal neovascularization are less likely to benefit from therapy. Use in more than one eye not studied. Standard precautions should be taken to avoid extravasation (e.g. free-flowing I.V. line, use of largest arm vein).